CMVLF (Cellectis) Dividends Received


CMVLF Cellectis SA CMVLF
60 GF Score
Price $3.47
GF Value $3.87
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cellectis Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

CMVLF
60GF Score
Cellectis SA CMVLF
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cellectis (CMVLF) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be undervalued. The current stock price of $3.47 is trading 10.3% below its estimated GF Value™ of $3.87. GuruFocus considers Cellectis to be Modestly Undervalued.

Key valuation signals for CMVLF:

  • Dividends Received:
  • GF Value™: $3.87 vs. price of $3.47 (10.3% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CMVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
60GF Score

Get the complete analysis for CMVLF

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.47
Price
$3.87
GF Value